Yale University

Qx Therapeutics Inc.

Enzo Biochem, Inc.

Enzo Therapeutics, Inc.

Li, Xiaofeng

Liu, Peng

Zhang, Yazhou

Zhang, Jie

Shan, Jufang

Engelhardt, Dean

Dianqing Wu

James J Donegan

Jie Zhang

Dakai Liu

Dean L Engelhardt

Xiaofeng Li

Le Sun

Ho Yin Lo

Yazhou Zhang

Abdul Basit

Wenwen Tang

Peng Liu

Jufang Shan

Bo Chen

Jie Zheng

Qianying Yuan

Hai Wu

Dean Engelhardt

The invention includes methods of preventing or treating acute lung injury using a MAP3K2/MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.

Compounds, compositions and methods of treating or preventing acute lung injury

The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.

Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections

The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of DKK2 gene depleting agent, methods for providing anti-tumor immunity and anti-tumor angiogenesis in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor angiogenesis in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.

Dickkopf2 (Dkk2) inhibition suppresses tumor formation

Compositions and methods for treating lung injuries associated with SARS-COV-2 infections

The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8cytotoxic T lymphocyte (CTL) activity, attenuates tumor, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of a humanized anti-DKK2 antibody, methods for providing anti-tumor immunity in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.

Humanized anti-DKK2 antibody and uses thereof

Growing community of inventors

Cheshire, CT, United States of America

Dianqing Wu